Recent Comments

Comment RSS

USPTO allows BioMarin's claims covering the approved administration of sapropterin dihydrochloride with food

1. October 2009 07:10

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that the United States Patent and Trademark Office has allowed claims covering the approved administration of Kuvan® (sapropterin dihydrochloride) with food, based on the discovery that food increases the bioavailability of Kuvan. The company expects that the patent, which expires in 2024, will officially issue later this year.

"This food effect patent, along with the patents issued for once daily dosing and stable tablet formulation, continues to strengthen our proprietary position on Kuvan and provides protection that extends approximately ten years beyond orphan drug exclusivity," said Jean-Jacques Bienaime, Chief Executive Officer of BioMarin. "We believe these patents will create significant barriers to therapeutically equivalent generic competition prior to their expiration."

SOURCE BioMarin Pharmaceutical Inc.

Posted in: Medical Patent News | Pharmaceutical News

Tags: , , , ,

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.

Add comment



(Will show your Gravatar icon)
  Country flag


biuquote
  • Comment
  • Preview
Loading



News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.